Amplia Therapeutics (ASX:ATX) said it opened two sites in the US, which will shortly start recruitment activities for its Amplicity trial, according to a Wednesday filing with the Australian bourse.
The trial will evaluate the company's lead drug, narmafotinib, in advanced pancreatic cancer patients, the filing said.
An additional three sites in the US will be initiated in the near future as recruitment continues, the filing added.
Shares of the company rose past 4% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.